238 related articles for article (PubMed ID: 25821194)
1. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.
Preti D; Baraldi PG; Moorman AR; Borea PA; Varani K
Med Res Rev; 2015 Jul; 35(4):790-848. PubMed ID: 25821194
[TBL] [Abstract][Full Text] [Related]
2. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
[TBL] [Abstract][Full Text] [Related]
3. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
4. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel and Selective Adenosine A
Tian S; Wang X; Li L; Zhang X; Li Y; Zhu F; Hou T; Zhen X
J Chem Inf Model; 2017 Jun; 57(6):1474-1487. PubMed ID: 28463561
[TBL] [Abstract][Full Text] [Related]
6. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
[TBL] [Abstract][Full Text] [Related]
7. A
Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
[TBL] [Abstract][Full Text] [Related]
8. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
9. 2-Benzylidene-1-Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions.
van Rensburg HJ; Legoabe L; Terre'Blanche G; Van der Walt M
Drug Res (Stuttg); 2019 Jul; 69(7):382-391. PubMed ID: 30616250
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives.
Al-Attraqchi OHA; Attimarad M; Venugopala KN; Nair A; Al-Attraqchi NHA
Curr Pharm Des; 2019; 25(25):2716-2740. PubMed ID: 31333093
[TBL] [Abstract][Full Text] [Related]
11. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A
Legoabe LJ; Van der Walt MM; Terre'Blanche G
Chem Biol Drug Des; 2018 Jan; 91(1):234-244. PubMed ID: 28734058
[TBL] [Abstract][Full Text] [Related]
13. Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity.
Koch P; Brunschweiger A; Namasivayam V; Ullrich S; Maruca A; Lazzaretto B; Küppers P; Hinz S; Hockemeyer J; Wiese M; Heer J; Alcaro S; Kiec-Kononowicz K; Müller CE
Front Chem; 2018; 6():206. PubMed ID: 29998095
[TBL] [Abstract][Full Text] [Related]
14. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
Van der Walt MM; Terre'Blanche G; Petzer A; Lourens AC; Petzer JP
Bioorg Chem; 2013 Aug; 49():49-58. PubMed ID: 23892098
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Structure Activity Relationships of Chalcone based Benzocycloalkanone Derivatives as Adenosine A1 and/or A2A Receptor Antagonists.
Janse van Rensburg HD; Legoabe LJ; Terre'Blanche G
Drug Res (Stuttg); 2020 Jun; 70(6):243-256. PubMed ID: 32349128
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Stössel A; Schlenk M; Hinz S; Küppers P; Heer J; Gütschow M; Müller CE
J Med Chem; 2013 Jun; 56(11):4580-96. PubMed ID: 23631427
[TBL] [Abstract][Full Text] [Related]
17. Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.
Cruz-Monteagudo M; Borges F; Cordeiro MNDS; Helguera AM; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Perera-Sardina Y; Perez-Castillo Y
Curr Neuropharmacol; 2017 Nov; 15(8):1117-1135. PubMed ID: 28093976
[TBL] [Abstract][Full Text] [Related]
18. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
19. A(2A) adenosine receptors and Parkinson's disease severity.
Casetta I; Vincenzi F; Bencivelli D; Corciulo C; Gentile M; Granieri E; Borea PA; Varani K
Acta Neurol Scand; 2014 Apr; 129(4):276-81. PubMed ID: 24032478
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
Popoli P; Pepponi R
CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
